News | April 03, 2012

PCI-Associated Renal Complications Increase Significantly Among Medicare Patients

Study warrants focus on contrast-induced nephropathy

April 3, 2012 — Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. Researchers said the findings warrant more focus on implementation of a contrast-induced nephropathy (CIN) protocol to reduce complications.

The study, conducted Oct. 1, 2008 to Sept. 30, 2010, was designed to report two-year trends in PCI-associated renal failure. The study group included all Medicare patients admitted for a PCI without CABG (coronary artery bypass graft) surgery or valve surgery in an acute care hospital. The study population was divided into two sub-samples:

  • Elective PCI: Patients who did not have primary ST segment elevation myocardial infarction (STEMI) and did not arrive in cardiogenic shock or cardiac arrest.
  • Non-Elective PCI: All MBs not undergoing an elective PCI.

 

All patients studied experienced significant increases in both acute renal failure (ARF) and new hemodialysis (HD) year over year, by 29 percent and 21 percent, respectively. The percentage increase for both complications was slightly higher for those patients undergoing elective PCI, while the increase in ARF among patients undergoing non-elective PCI was nearly double that of elective patients.

“The rise in renal complications is concerning, given their close association with worse morbidity and mortality,” said April Simon, R.N., MSN, one of the researchers and president of Cardiac Data Solutions, which conduced the study. “This data suggests that increased focus on contrast-induced nephropathy prevention protocols may improve clinical outcomes. Any patient receiving contrast is at risk for CIN; insuring that the amount of contrast is minimized and paying particular attention to hydration are imperative.”

For more information: www.ereleases.com/pic/Cardiac-Data-Solutions.pdf.

Related Content

High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR
Technology | Angiography | May 22, 2018
Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for...
360 Photos | Angiography | May 03, 2018
A 360 degree view of the newest cath lab at...
Guideline updates and clinical research highlight the need for improved understanding of gender differences by clinicians and patients
Feature | Women's Health | May 03, 2018 | By Jeff Zagoudis
Clinical research has revealed men and women often have different presentations for cardiovascular disease (CVD).
GE's OEC Elite CFD

GE's OEC Elite CFD

Feature | Mobile C-Arms | April 18, 2018 | Jeff Zagoudis
The market for mobile C-arm techn...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Overlay Init